With everyone's attention focused on major macroeconomic shocks, important trends from the last six months have largely gone unnoticed. So instead of rehashing how Italy's increasing borrowing costs continue to jeopardize the euro's long-term viability, let's talk health care, because it's stomping the markets in 2012.
Over the last six months, the health-care sector has returned a whopping 29.6%, nearly 10 times better than the Dow Jones'
Let's take a closer look at how the three major indexes are faring.
|Index||Gain/Loss||Gain/Loss %||Intraday Value|
|Dow Jones Industrial Average||1.36||0.01%||12,575.16|
Source: Yahoo! Finance.
Don't let the flatness fool you; all three indexes were down significantly at the beginning of the day. Unsurprisingly, the markets' "fear index" has seen a spike; the VIX
The largest Dow component, Johnson & Johnson
J&J also received excellent results from diabetes treatment canagliflozin, as it beat the current standard of care, Merck's Januvia. Diabetes, a growing problem in this country, is gaining additional attention from big pharma. Amylin
Arena has gone on an incredible run, but there are other game-changing revolutions happening at the cutting edge of health care. Motley Fool Co-Founder David Gardner has uncovered a small company with the ability to radically improve how a common and growing procedure is performed. We invite you to download The Motley Fool's special report, "Discover the Next Rule-Breaking Multibagger." It's free for a limited time only. Click here to get a leg up on Wall Street.
David Williamson owns shares of Johnson & Johnson, but holds no positions in any other companies mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of JPMorgan Chase and Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson. Motley Fool newsletter services have also recommended creating a diagonal call position in Johnson & Johnson. The Motley Fool has a disclosure policy.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.